Deal-Making

thumbnail
Deal-Making
Astellas’ Xyphos, Kelonia ink $800m cancer-focused partnershipAstellas’ Xyphos, Kelonia ink $800m cancer-focused partnership

Astellas subsidiary Xyphos and Kelonia Therapeutics have signed a research and licensing deal worth $800 million to develop immuno-oncological therapies.

byShreeyashi Ojha, Reporter
Feb 19, 2024
|
1 Min Read
thumbnail
Deal-Making
Multiply Labs and Thermo Fisher expand cell therapy partnershipMultiply Labs and Thermo Fisher expand cell therapy partnership
byMillie Nelson
Feb 14, 2024
1 Min Read
thumbnail
Deal-Making
Incyte gains Monjuvi as Novartis acquires MorphoSysIncyte gains Monjuvi as Novartis acquires MorphoSys
byShreeyashi Ojha
Feb 12, 2024
1 Min Read
thumbnail
Deal-Making
Lonza, Oxford Nanopore to expedite mRNA analysisLonza, Oxford Nanopore to expedite mRNA analysis
byShreeyashi Ojha
Feb 12, 2024
1 Min Read
thumbnail
Deal-Making
Samsung Biologics teams with LegoChem to advance ADCsSamsung Biologics teams with LegoChem to advance ADCs
byMillie Nelson
Feb 12, 2024
1 Min Read
thumbnail
Deal-Making
BioNTech inks $250m deal with Autolus to develop CAR-T assetsBioNTech inks $250m deal with Autolus to develop CAR-T assets
byMillie Nelson
Feb 12, 2024
1 Min Read
Deal-Making
Purolite and Repligen team on affinity resins for purification of mAbs
Purolite and Repligen team on affinity resins for purification of mAbs
Feb 8, 2024
|
1 Min Read
byShreeyashi Ojha, Reporter
Deal-Making
CDMOs Biovian and 3P eye global strategy through merger
CDMOs Biovian and 3P eye global strategy through merger
Feb 8, 2024
|
1 Min Read
byShreeyashi Ojha, Reporter
Therapeutic Class
Novo Catalent deal primed to shake up CGT outsourcing space
Novo Catalent deal primed to shake up CGT outsourcing space
Feb 8, 2024
|
1 Min Read
byDan Stanton, Editorial director
Facilities & Capacity
Novo Holdings $16.5bn Catalent buy to boost fill-finish for Novo Nordisk
Novo Holdings to buy CDMO Catalent for $16.5bn
Feb 5, 2024
|
1 Min Read
byDan Stanton, Editorial director
Deal-Making
Serum Institute of India joins CEPI for preparedness against ‘Disease X’
Serum Institute of India joins CEPI for preparedness against ‘Disease X’
Feb 5, 2024
|
1 Min Read
byShreeyashi Ojha, Reporter
Deal-Making
Vivtex, Astellas partner on oral biologic Gut-on-Chip tech
Vivtex, Astellas partner on oral biologic Gut-on-Chip tech
Feb 5, 2024
|
1 Min Read
byShreeyashi Ojha, Reporter
Deal-Making
2seventy deal to bulk out Regeneron’s cell therapy pipeline
2seventy deal to bulk out Regeneron’s cell therapy pipeline
Feb 1, 2024
|
1 Min Read
byShreeyashi Ojha, Reporter
Deal-Making
Resilience selects VGXI for pDNA supply
Resilience selects VGXI for pDNA supply
Jan 30, 2024
|
1 Min Read
byMillie Nelson, Editor
Deal-Making
Sandoz picks up Coherus’ Lucentis for $170m
Sandoz picks up Coherus’ Lucentis for $170m
Jan 26, 2024
|
1 Min Read
byMillie Nelson, Editor
Deal-Making
BlueRock to commercialize ocular disease treatment
BlueRock to commercialize ocular disease treatment
Jan 25, 2024
|
1 Min Read
byShreeyashi Ojha, Reporter
Deal-Making
Fujifilm SHL partner to meet growing autoinjector demands
Fujifilm SHL partner to meet growing autoinjector demands
Jan 12, 2024
|
1 Min Read
byShreeyashi Ojha, Reporter
Deal-Making
VC firm Flagship forms tech and trials deal with Samsung
VC firm Flagship forms tech and trials deal with Samsung
Jan 11, 2024
|
1 Min Read
byGareth Macdonald
Deal-Making
GSK ups respiratory pipeline with $1.4bn Aiolos Bio buy
GSK ups respiratory pipeline with $1.4bn Aiolos Bio buy
Jan 10, 2024
|
1 Min Read
byMillie Nelson, Editor
Deal-Making
Merck to buy T-cell engager firm Harpoon for $680m
Merck to buy T-cell engager firm Harpoon for $680m
Jan 8, 2024
|
1 Min Read
byDan Stanton, Editorial director
Deal-Making
J&J bolstering ADC pipeline through $2bn Ambrx acquisition
J&J bolstering ADC pipeline through $2bn Ambrx acquisition
Jan 8, 2024
|
1 Min Read
byShreeyashi Ojha, Reporter
Deal-Making
BMS bolsters oncology portfolio with $4.1bn RayzeBio buy
BMS bolsters oncology portfolio with $4.1bn RayzeBio buy
Jan 4, 2024
|
1 Min Read
byShreeyashi Ojha, Reporter
Deal-Making
AstraZeneca accelerates cell therapy ambitions through Gracell buy
AstraZeneca accelerates cell therapy ambitions through Gracell buy
Jan 2, 2024
|
1 Min Read
byShreeyashi Ojha, Reporter
Aquisition
Deal-Making
Novartis sells France CGT biz to Seqens
Novartis sells France CGT biz to Seqens
Dec 19, 2023
|
1 Min Read
byShreeyashi Ojha, Reporter
Cancer
Deal-Making
Merck taps into C4T’s degrader-antibody conjugate tech
Merck taps into C4T’s degrader-antibody conjugate tech
Dec 18, 2023
|
1 Min Read
byShreeyashi Ojha, Reporter
UCL
Deal-Making
ViroCell inks CAR-T manufacturing pact with UCL
ViroCell inks CAR-T manufacturing pact with UCL
Dec 18, 2023
|
1 Min Read
byMillie Nelson, Editor
Acquisition
Deal-Making
AstraZeneca adds respiratory vaccine pipeline through $1.1bn Icosavax deal
AstraZeneca adds respiratory vaccine pipeline through $1.1bn Icosavax deal
Dec 14, 2023
|
1 Min Read
byShreeyashi Ojha, Reporter
Pfizer
Deal-Making
Done and dusted: Pfizer completes $43bn Seagen deal
Done and dusted: Pfizer completes $43bn Seagen deal
Dec 14, 2023
|
1 Min Read
byDan Stanton, Editorial director
logo in a gray background |
Deal-Making
Ins and Outs, High level changes at CDMOs
Ins and Outs, High level changes at CDMOs
Dec 13, 2023
|
1 Min Read
byShreeyashi Ojha, Reporter
China
Deal-Making
China riding high on the ADC partnership wave
China riding high on the ADC partnership wave
Dec 13, 2023
|
1 Min Read
byMillie Nelson, Editor
Partnership
Deal-Making
Abzena taps into ProteoNic’s viral vector tech
Abzena taps into ProteoNic’s viral vector tech
Dec 11, 2023
|
1 Min Read
byShreeyashi Ojha, Reporter
bispecific deal
Deal-Making
AGC Bio and Immunocore ink bispecific deal
AGC Bio and Immunocore ink bispecific deal
Dec 11, 2023
|
1 Min Read
bySara Healy
logo in a gray background |
Deal-Making
Oxford Biomedica acquires ABL Europe
Oxford Biomedica acquires ABL Europe
Dec 7, 2023
|
1 Min Read
byShreeyashi Ojha, Reporter
Roche weighs in on obesity drug market with $2.7bn Carmot buy
Deal-Making
Roche weighs in on obesity drug market with $2.7bn Carmot buy
Roche weighs in on obesity drug market with $2.7bn Carmot buy
Dec 4, 2023
|
1 Min Read
byMillie Nelson, Editor
Oblique
Deal-Making
Oblique taps into AAX’s seqitope tech
Oblique taps into AAX’s seqitope tech
Dec 1, 2023
|
1 Min Read
byShreeyashi Ojha, Reporter

Webinars

Ask the Expert webcasts
ATE Webcasts
Register Now: Big Impact from Small Samples: Harnessing High-Precision Tunable Laser Spectroscopy for Complex Bioprocessing Analysis
Register Now: Big Impact from Small Samples: Harnessing High-Precision Tunable Laser Spectroscopy for Complex Bioprocessing Analysis
Ask the Expert webcasts
ATE Webcasts
Register Now: Advancing mRNA and CircRNA-based Vaccines and Therapeutics in CMC: From Process Development to Analytics
Register Now: Advancing mRNA and CircRNA-based Vaccines and Therapeutics in CMC: From Process Development to Analytics
Insider News
See all
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More

Innovative Technology

Nagase Trehalose SG
Sponsored Content
Innovative Impurity Reduction in Harvesting Process With TREHALOSE SG
Innovative Impurity Reduction in Harvesting Process With TREHALOSE SG

Jan 9, 2025

Bruker Tornado Spectroscopy
Sponsored Content
Monitoring and Controlling Upstream Bioprocesses with Raman Spectroscopy
Monitoring and Controlling Upstream Bioprocesses with Raman Spectroscopy

Dec 1, 2024

Thermo Fisher White Paper
Sponsored Content
Peptones: A Powerful Tool for Manufacturing Complex Protein Therapies
Peptones: A Powerful Tool for Manufacturing Complex Protein Therapies

Nov 21, 2024

Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.
Subscribe